文献速递毛发、甲与色素性疾病自身免疫性与大疱性皮肤病

外用芦可替尼治疗非节段性白癜风的真实世界疗效:860例多中心研究

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
PubMed 文献 · Br J Dermatol · 2026-08-17

夏季开始治疗和Koebner现象独立预测24周F-VASI75,焦虑抑郁评分持续改善,耐受性良好。

要点

  • 夏季开始治疗与Koebner现象独立预测24周F-VASI75
  • 基线37%有中重度焦虑,24周降至11%,52周降至2%

核心结论

  • 在异质性远高于注册试验人群的真实世界大样本中,外用芦可替尼至52周显示渐进性复色且耐受性极佳。
  • 夏季开始治疗和Koebner现象独立预测早期应答,可指导患者咨询和前瞻性研究设计。
  • 焦虑和抑郁持续平行下降,支持将标准化心理健康评估作为白癜风常规诊疗组成部分。

研究设计与样本

  • 多中心回顾性队列研究,覆盖意大利34个皮肤科中心,时间为2024年7月至2025年10月。
  • 主要结局为24周和52周的F-VASI75与F-VASI90;次要结局包括VNS、DLQI、VitiQoL、GAD-7和PHQ-9。

主要发现

  • 基线37%患者有中重度焦虑(GAD-7≥10),24周降至11%,52周降至2%;VitiQoL、DLQI和PHQ-9在所有时间点均改善。

关键数值与推荐

  • 基线GAD-7≥10者占37%,24周为11%,52周为2%。

临床怎么用

  • 夏季开始治疗和合并Koebner现象者可能更早出现F-VASI75应答,可用于患者咨询。
  • 应常规评估焦虑抑郁(如GAD-7、PHQ-9),因治疗期间心理健康指标持续改善。
  • 耐受性良好,轻度不良事件占绝大多数,停药率低。

局限性

  • 真实世界人群异质性高,可能影响结果外推。
  • 原文未报告盲法、对照设置或混杂因素控制的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitiligo affects 0·5-2% of the global population and carries a substantial psychosocial burden. Topical ruxolitinib 1·5% cream is approved for non-segmental vitiligo based on phase-3 trial data, but real-world evidence across heterogeneous populations remains limited. OBJECTIVES: To evaluate the real-world effectiveness, safety, and patient-reported outcomes of topical ruxolitinib across 34 Italian dermatology centres, and to identify possible clinical predictors of treatment response. METHODS: Multicentre retrospective cohort study (July 2024-October 2025). Patients (≥12 years) with non-segmental vitiligo received ruxolitinib 1·5% cream twice daily. Primary outcomes were F-VASI75 and F-VASI90 at 24 and 52 weeks. Secondary outcomes were VNS, DLQI, VitiQoL, GAD-7, and PHQ-9. RESULTS: 860 patients (mean age 47 years; 58% female; disease duration 13·5 years; 84% previously treated) completed 24-week assessment; 229 (26·6%) had reached 52 weeks at the time of data lock. F-VASI75 was achieved by 18·5% at 24 weeks, increasing to 38·4% at 52 weeks; F-VASI90 rose from 5·7% to 25·8%. In multivariable logistic regression, summer treatment initiation (adjusted OR 6·7, 95% CI 2·7-16·8) and Koebner phenomenon (adjusted OR 1·6, 95% CI 1·04-2·66) were independent predictors of F-VASI75 at 24 weeks. At baseline, 37% of patients had moderate-to-severe anxiety (GAD-7 ≥10); this fell to 11% at 24 weeks and 2% at 52 weeks. VitiQoL, DLQI, and PHQ-9 improved at all timepoints. Adverse events were mild in 98·9%; treatment discontinuation rate was 1·5%. CONCLUSIONS: In a large real-world population considerably more heterogeneous than registration trial cohorts, topical ruxolitinib showed progressive repigmentation through 52 weeks with excellent tolerability. Summer initiation and Koebner phenomenon independently predicted early response, findings that may inform patient counselling and the design of prospective studies. The parallel sustained reduction in anxiety and depression argues for standardised mental health assessment as a routine component of vitiligo care.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Marzano AV, Narcisi A, Tavoletti G, et al. Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study. Br J Dermatol. 2026. PMID: 42605165. doi:10.1093/bjd/ljag342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。